Review of guidelines on the treatment of metastatic renal cell carcinoma

Guidelines on the management of metastatic renal cell carcinoma (rcc) have emerged over the last couple of years because of the introduction of effective new targeted therapies. However, current guidelines are not always contemporary because of older data whose relevance is unclear in the context of the new therapies. Moreover, many of the relevant trials were interrupted prematurely because of significant advantages in progression-free survival. These circumstances sometimes make interpretation of the data and characterization of subgroups rather difficult. The current paper reviews the major guidelines available on the management of metastatic rcc and tries to put them into context.

[1]  J. Knox,et al.  Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[2]  J. Knox,et al.  Canadian kidney cancer forum 2008. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[3]  G. Bjarnason,et al.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[4]  J. Marrero,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  B. Rini,et al.  A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer , 2009, Cancer.

[6]  R. Motzer,et al.  Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. , 2008, Clinical genitourinary cancer.

[7]  M. Kattan,et al.  Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.

[8]  S. McKenna,et al.  Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. , 2008, Biochemical Society transactions.

[9]  J. Patard,et al.  Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. , 2008, European urology.

[10]  R. Motzer,et al.  Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[11]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[12]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[13]  R. Prentice Use of the logistic model in retrospective studies. , 1976, Biometrics.

[14]  Lorenzo Marconi,et al.  Guidelines on Renal Cell Carcinoma , 2007 .